Tehrani K, Tajik A. Efficacy of erythropoietin in patients with ischemic stroke[J]. Iran J Neurol, 2013, 12(1): 132.
[2]
Lippi G, Franchini M, Favaloro E J. Thrombotic complications of erythropoiesis-stimulating agents[J]. Semin Thormb Hemost, 2010, 36(5): 537.
[3]
Liu K, Sun T, Wang P, et al. Effects of erythropoietin on blood-brain barrier tight hunctions in ischemia-reperfusion rats[J]. J Mol Neurosci, 2013, 49(2): 369.
[4]
Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain:evidence from an in vitro model [J].Neurosci, 2002, 22(23):10291.
Digicayliogiu I, Garden G, Timberlake S, et al. Acute neuroprotective synergy of erythrop-oietin and insulin-like growth factor Ⅰ[J].Proc Nati Acad Sci USA, 2004, 101(26):9855.
[7]
Erdogan Ozturk, Semra Demirbilek, Ahmet K？ro？lu, et al. Propofol and erythropoietin antioxidant properties in rat brain injured tissue [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(1):81.
[8]
Kumral A, Gonenc S, Acikgoz O, et al. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats[J]. Neonatology, 2005, 87(1): 15.
[9]
Manfrfed Nairz, Andrea Schroll, Alexander G Moschen, et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways[J]. Immunity, 2011.34(1): 61.
[10]
Nairz M, Sonnweber T, Schroll A, et al. The pleiotropic effects of erythropoietin in infection and inflammation[J]. Microbes, 2012, 14(3): 238.
[11]
Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells[J]. Proc Natl Acad Sci USA, 1994, 91(9):3974.
[12]
Zwezdaryk K J, Coffelt S B, Figueroa Y G, et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells[J]. Exp Hematol, 2007, 35(4): 640.
[13]
Xu Y, Tian Y, Wei H J, et al. Erythropoietin increases circulating endothelial progenitor cells and reduces the formation and progression of cerebral aneurysm in rats[J]. Neuroscience, 2011, 181(5): 292.
[14]
Souvenir R, Fathali N, Ostrowski R P, et al. Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia[J]. Neurobiol Dis, 2011, 44(1): 28.
Chavez J C, Baranova O, Lin J, et al. The transsriptional activator hypoxia inducible factor 2(HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes[J].J Neurosci, 2006, 26(37): 9471.
[44]
Mei Yee Koh, Taly R Spivak-Kroizman, Garth Powis. HIF-1 regulation: not so easy come, easy go[J]. Trends Biochem Sci, 2008, 33(1): 526.
[45]
Reiling, J H, Sabatini D M. Stress and mTORture signaling[J]. Oncogene, 2006, 25(48):6373.
[46]
Yang Xiu-Mei, Wang Yu-Sheng, Zhang Jian, et al. Role of PI3K/Akt and MEK/ERK in mediating hypoxiaInduced expression of HIF-1 and VEGF in laser induced rat choroida-l neovascularization [J]. Invest Ophthalmol Vis Sci, 2009, 50(4):1873.
[47]
Yanira G Figueroa, Anna K Chan, Rania Ibrahim, et al. NF-κB plays a key role in h-ypoxia-inducible factor-1 regulated erythropoietin gene expression[J]. Exp Hematol, 2002, 30(12):1419.
Zhang X, Shi M, Bj？r？s M, et al. Ginsenoside Rd promotes glutamate clearance by up-regulating glial glutamate transporter GLT-1 via PI3K/AKT and ERK1/2 pathways[J]. Front Pharm, 2013, 61(12):1959.
Chen S F, Tsai H J, Hung T H, et al. Salidroside improves behavioral and histological outcomes and reduces apoptosis via PI3K/Akt signaling after experimental traumatic brain injury[J]. PLoS ONE, 2012, 7(9): 45763.
